Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D013119: Spinal Cord Injuries

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (9)


Name (Synonyms) Correlation
drug4928 eM2M Wiki 0.38
drug1863 Heated Vest Wiki 0.38
drug4738 WebEx Physical Activity Program Wiki 0.38
Name (Synonyms) Correlation
drug4610 VIP4SCI Wiki 0.38
drug3588 ReWalk 6.0 Wiki 0.38
drug2850 Non-Heated Vest Wiki 0.38
drug990 Ciclesonide Wiki 0.27
drug986 Cholecalciferol Wiki 0.17
drug3195 Placebo Wiki 0.02

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D016135 Spinal Dysraphism NIH 0.38
D014947 Wounds and Injuries NIH 0.25
D002547 Cerebral Palsy NIH 0.22
Name (Synonyms) Correlation
D001930 Brain Injuries, NIH 0.21
D000070642 Brain Injuries, Traumatic NIH 0.13
D010300 Parkinsonian NIH 0.11
D009103 Multiple Sclerosis NIH 0.09

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002414 Spina bifida HPO 0.38
HP:0001264 Spastic diplegia HPO 0.22

Clinical Trials

Navigate: Correlations   HPO

There are 7 clinical trials


1 CSP #2003 - Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life

Background Veterans with spinal cord injury (SCI) have many adverse secondary medical and quality of life (QOL) changes as a result of immobilization. Veterans with SCI who have completed rehabilitation after injury and are unable to ambulate receive a wheelchair as standard of care (SOC) for mobility. Powered exoskeletons are a technology that has recently become available as an alternate form of mobility by providing an external framework for support and computer controlled motorized hip and knee joints to assist with over ground ambulation.

NCT02658656
Conditions
  1. Spinal Cord Injury
Interventions
  1. Device: ReWalk 6.0
MeSH:Spinal Cord Injuries

Primary Outcomes

Description: The Veterans RAND 36 Item Health Survey (VR-36) is a brief, generic, multi-use, self-administered health survey comprised of 36 items. The instrument is primarily used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific impact on general and selected populations. The items on the questionnaire correspond to eight principal health domains including general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning and mental health. The outcome in this study is the score from the Mental Health Component Summary (MCS) of the VR-36, which measures the vitality, social functioning, role-emotional, and mental health of the participant.

Measure: Mental Health Component Summary (MCS) of the Veterans Rand-36 (VR-36)

Time: Change from Baseline Assessment to 4 Months Post Intervention

Description: The Spinal Cord Injury - Quality of Life (SCI-QOL) measurement tool was developed to assess patient reported outcome measures in persons with SCI. It is comprised of four broad domains of physical-medical health, emotional health, social participation, and physical functioning. Primary Outcome #2 will be a sum of the scores on the Bladder Management Difficulties, Bowel Management Difficulties, and Pain Interference item banks within the Physical-Medical Health domain.

Measure: The sum T-score for the SCI-QOL Physical Medical Health domain (three item banks of Bladder Management Difficulties, Bowel Management Difficulties, and Pain Interference)

Time: Change from Baseline Assessment to 4 Months Post Intervention

Secondary Outcomes

Description: Total body fat mass as measured by DXA (Dual energy X-Absorptiometry) scan.

Measure: Total Body Fat Mass (Kg)

Time: Change from Baseline Assessment to 4 Months Post Intervention
2 Developing a Feedback-Controlled Heated Vest to Address Thermoregulatory Dysfunction in Persons With Spinal Cord Injury

Persons with higher levels of spinal cord injury (above the 2nd thoracic vertebrae; tetraplegia) are unable to maintain normal core body temperature (Tcore) when exposed to cool environments. In persons with tetraplegia, even limited exposure to cool temperatures may cause Tcore to approach hypothermic values and impair cognitive performance. Conversely, an increase in Tcore from subnormal to normal range may improve cognitive performance. Prior work has shown that cool seasonal temperatures have an adverse effect on personal comfort and the ability to perform vital daily activities of self-care in persons with tetraplegia. Interventions that address the vulnerability to hypothermia are limited. A self-regulating heated vest designed specifically for persons with tetraplegia is a novel and promising strategy to address this problem. By more effectively maintaining Tcore, the vest can decrease the adverse impact of cool temperatures on comfort, quality of life, and performance of vital daily tasks for Veterans with tetraplegia during the cooler seasons.

NCT03662308
Conditions
  1. Spinal Cord Injuries
Interventions
  1. Device: Heated Vest
  2. Device: Non-Heated Vest
MeSH:Spinal Cord Injuries Wounds and Injuries

Primary Outcomes

Description: Tcore will be continuously monitored throughout baseline and thermal challenge periods (with heated & non-heated vests) by a TX-2 Rectal probe and Iso-Thermex Multichannel Thermometer (Columbus Instruments, Columbus, OH). The probe will be placed 10 cm beyond the anal sphincter.

Measure: Change in Core Body Temperature (Tcore)

Time: Visits 2 & 3 (subjects with tetraplegia only): Continuously throughout baseline & Thermal Challenge (2 hrs) periods. The change in Tcore from baseline to the end of Thermal Challenge will be determined.

Description: The cognitive battery will be administered once at BL and once after Thermal Challenge in persons with tetraplegia only (Visits 2 & 3). Testing conditions will be identical, quiet, and distraction-free. Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV): Subjects will be asked to repeat 2-9 numbers forward, backward and in ascending order to assess attention, processing speed, and working memory. Each assessment requires 10 min.

Measure: Change in Cognitive Performance: WAIS-IV

Time: Visits 2 & 3 (subjects with tetraplegia only): At the end baseline (at 15 min) & end of Thermal Challenge (at 120 min) periods. The change in cognitive performance from baseline to the end of Thermal Challenge will be determined.

Description: Delayed Recall section of the Montreal Cognitive Assessment (MoCA): Subjects will be asked to repeat 5 simple words immediately and then recall them after a 5-minute delay to assess working memory. Each assessment requires 6 min.

Measure: Change in Cognitive Performance: Delayed Recall

Time: Visits 2 & 3 (subjects with tetraplegia only): At the end baseline (at 15 min) & end of Thermal Challenge (at 120 min) periods. The change in cognitive performance from baseline to the end of Thermal Challenge will be determined.

Description: Stroop Color and Word: Subjects will be asked to read words of colors, colors of fonts to assess attention and processing speed; color of fonts of words which describe conflicting colors to assess response inhibition (executive functioning). Subjects will practice each of the assessments for approximately 10 seconds prior to the actual test to ensure understanding of the instructions. Each assessment requires 4 min.

Measure: Change in Cognitive Performance: Stroop

Time: Visits 2 & 3 (subjects with tetraplegia only): At the end baseline (at 15 min) & end of Thermal Challenge (at 120 min) periods. The change in cognitive performance from baseline to the end of Thermal Challenge will be determined.

Secondary Outcomes

Description: Thermal Comfort will be measured every 10 minutes throughout BL and thermal challenge periods by the Zhang 6-point thermal comfort scale: +3 (very comfortable), +2 (comfortable), +1 (just comfortable), -1 (just uncomfortable), -2 (uncomfortable), and -3 (very uncomfortable). A greater frequency of +1, +2, and +3 scores are considered more desirable than -1, -2, and -3 scores during the Thermal Challenge. Each assessment requires only the time needed for the subject to respond (typically less than 10 seconds).

Measure: Change in Thermal Comfort (TC)

Time: Visits 1, 2, & 3 (all subjects): During baseline & every 10 minutes throughout Thermal Challenge (2 hrs). The change in TC from baseline to the end of Thermal Challenge will be determined.

Other Outcomes

Description: Skin thermocouples (TX-4 Skin Surface probes, Columbus Instruments, Columbus, OH) will be taped to 12 sites on the anterior trunk. Tsk data will be collected continuously throughout the baseline (BL) and Thermal Challenge periods. All areas under the vest will have skin temperatures less than or equal to 39 degrees C.

Measure: Change in Skin Temperature (Tsk) under the heated vest

Time: Visits 2 & 3 (all subjects): Continuously throughout baseline (15 min) & Thermal Challenge (2 hrs) periods. The change in Tsk from baseline to the end of Thermal Challenge will be determined.

Description: Thermal sensation will be measured on the Zhang 9-point Thermal Sensation scale: +4 (very hot), +3 (hot), +2 (warm), +1 (slightly warm), 0 (neutral), -1 (slightly cool), -2 (cool), -3 (cold), and -4 (very cold). TS should be no greater than "warm" this would include identification of "hot spots". Each assessment requires only the time needed for the subject to respond (typically less than 10 seconds).

Measure: Change in Thermal Sensation (TS)

Time: Visit 1 (able-bodied subjects only): During baseline & every 10 minutes throughout Thermal Challenge (2 hrs). The change in TS from baseline to the end of Thermal Challenge will be determined.
3 The M2M LEADERS Project: Lakeshore Examination of Activity, Disability, and Exercise Response Study (LEADERS)

The purpose of this study is to test the effects of an innovative exercise program referred to as movement-2-music (M2M) on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants with physical/mobility disabilities will be recruited and randomly enrolled into one of two groups: a) M2M or b) waitlist control. The primary aim of this study is to determine the effects of a 12-week M2M program on health and fitness in participants with physical/mobility disabilities who are in one of three functional mobility groups: 1) Group I - only able to exercise while sitting, 2) Group II - able to exercise sitting and standing with/without support, and 3) Group III - able to exercise one side of the body more than the other side. The second aim is to compare the observed effects of the program in this study to a previous M2M study that groups participants based on disability type. The third aim of this study is to test whether adherence (defined as attendance to the 12-week program) affects the effects of M2M in participants with physical/mobility disabilities. The potential influences of different functional mobility and disabilities of participants on how the program affects participants' health and fitness outcomes will also be tested. **In response to COVID-19, the 12-week M2M intervention and all assessments have been modified from being delivered in-person at Lakeshore Foundation to being delivered remotely in real-time through videoconferencing technology.**

NCT03797378
Conditions
  1. Spinal Cord Injuries
  2. Traumatic Brain Injury
  3. Spina Bifida
  4. Cerebral Palsy
  5. Stroke
  6. Parkinson Disease
  7. Multiple Sclerosis
Interventions
  1. Other: eM2M
MeSH:Parkinson Disease Multiple Sclerosis Brain Injuries Spinal Cord Injuries Brain Injuries, Traumatic Cerebral Palsy Spinal Dysraphism Wounds and Injuries
HPO:Athetoid cerebral palsy Cerebral palsy Spastic diplegia Spina bifida

Primary Outcomes

Description: The cardiorespiratory fitness is measured using a heart rate recovery test

Measure: Change from baseline cardiorespiratory fitness at 3 months

Time: Baseline and post 12-week intervention

Description: Muscle strength is measured with grip strength using a hand-held dynamometer.

Measure: Change from baseline muscle strength at 3 months

Time: Baseline and post 12-week intervention

Secondary Outcomes

Description: Lower extremity function is assessed using the Short Physical Performance Battery (SPPB)

Measure: Change from baseline lower extremity function at 3 months

Time: Baseline and post 12-week intervention

Description: Lower extremity function will be assessed using the Timed Up and Go (TUG) test.

Measure: Change from baseline lower extremity function at 3 months

Time: Baseline and post 12-week intervention

Description: Health-related quality of life is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 Health Items. The instrument is a 10-item measure with the response scores ranging from 1 (very severe) to 5 (none). Two summary scores, a global physical health score and a global mental health score, can be calculated from this scale, with each score ranging from 4 to 20. Higher scores indicate better health. The total raw score is translated into a T-score for each participant for analysis.

Measure: Change from baseline health-related quality of life at 3 months

Time: Baseline and post 12-week intervention

Description: Social participation is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities. The instrument is a 8-item measure with the response scores ranging from 1 (always) to 5 (never). The lowest possible total raw score is 8 and the highest possible score is 40. Higher scores indicate better ability to participate in social roles and activities. The total raw score is translated into a T-score for each participant for analysis.

Measure: Change from baseline social participation at 3 months

Time: Baseline and post 12-week intervention

Description: Physical activity is measured using the Godin Leisure Time Exercise Questionnaire. The questionnaire contains two questions. The first question asks participants to report weekly frequencies of activities they perform at different intensities. A total weekly leisure activity is a sum of activity scores calculated by multiplying the weekly frequencies of strenuous, moderate, and light activities by 9, 5, and 3, respectively. The second question asks participants the frequency of weekly leisure-time activities performed that are long enough to work up a sweat.

Measure: Change from baseline physical activity at 3 months

Time: Baseline and post 12-week intervention

Other Outcomes

Description: Barriers in physical activity will be assessed using the Barriers in Physical Activity Questionnaire. The instrument contains 43 items. Each item is responded with either no (1) or yes (2). If response is yes, a follow-up response that ranges from 1 (very small) to 5 (very large) is selected. There are 8 domains, which include personal health, attitudes/beliefs towards physical activity, friends, family, fitness center built environment, policy/programs/staff, community built environment, and safety. Each domain score is calculated by summing the item responses with its respective item weight. Higher domain scores indicate greater perceived barriers to physical activity.

Measure: Change from baseline barriers in physical activity at 3 months

Time: Baseline and post 12-week intervention

Description: Exercise self-efficacy will be assessed using the Exercise Self-Efficacy Scale. The scale contains 8 items, with response options of each item ranging from 0% (not at all confident) to 100% (highly confident). All items are summed and a mean score is calculated. Higher scores indicate higher levels of self-efficacy.

Measure: Change from baseline exercise self-efficacy at 3 months

Time: Baseline and post 12-week intervention

Description: Exercise goal-setting will be measured using the Exercise Goal-Setting Scale. The instrument contains 10 items with response options ranging from 1 (does not describe) to 5 (describes completely). A mean score is calculated. A higher mean score indicate better goal-setting and self-monitoring for exercise.

Measure: Change from baseline exercise goal-setting at 3 months

Time: Baseline and post 12-week intervention

Description: Outcome expectations for exercise will be assessed using the Multidimensional Outcome Expectations for Exercise Scale. The instrument contains 15 items, with the response options ranging from 1 (strongly disagree) to 5 (strongly agree). Three domains of outcome expectations for exercise are assessed, which include physical outcome expectations (6 items), social outcome expectations (4 items), and self-evaluative outcome expectations (5 items). Each dimension is scored by summing the item responses. Higher scores indicate higher levels of outcome expectations for exercise.

Measure: Change from baseline outcome expectations for exercise at 3 months

Time: Baseline and post 12-week intervention

Description: Social support will be assessed using the Social Provision Scale. The instrument contains 24 items, with the response options ranging from 1 (strongly disagree) to 4 (strongly agree). A total score is calculated by summing scores from all items. A higher score indicates a greater degree of perceived support.

Measure: Change from baseline social support at 3 months

Time: Baseline and post 12-week intervention
4 Improving Activity Engagement Among Persons With SCI During COVID-19

During the current COVID-19 pandemic many spinal cord injury (SCI) rehabilitation services are limited to emergency management, leaving those living in the community without access to services. Unfortunately, this can lead to negative effects including increase in emotional distress, feelings of isolation, and decreased activity engagement. Due to their limited mobility and greater likelihood of respiratory illness it is imperative to provide alternative forms of activity engagement to reduce their risk for secondary complications. Physical activity has been demonstrate to have numerous benefits for individuals with SCI ranging from enhanced health through prevention of secondary complications to improved subjective well-being. The current study proposes to provide an online physical activity program through web-based videoconferencing to person with SCI to improve overall wellbeing and activity engagement. The program will consist of six weeks of twice-weekly, 45-minute sessions in which an experienced fitness instructor (i.e., wheelchair aerobics) with lived experience and a Kinesiology graduate student will lead online sessions. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and guided meditation. In all cases, remote (i.e., in-home) participant monitoring of physiological signals will be conducted by the instructor to ensure safety of participants. Once the program has been completed, participants will be asked to complete self-report questionnaires related to acceptability, feasibility, and limited effectiveness. Participants will also be asked to complete a brief semi-structured interview examining barriers and facilitators of the program. Participant feedback from the interviews will be used to further develop of the program to meet the needs of the population and develop sustainable approaches for access to care in the community setting through collaborations with community partners (SCI Ontario, National SCI Alliance, Ontario Neurotrauma Foundation). Ultimately, the proposed project aims to improve overall wellbeing and access to health care service for those with SCI during the COVID-19 quarantine.

NCT04408287
Conditions
  1. Spinal Cord Injuries
Interventions
  1. Other: WebEx Physical Activity Program
MeSH:Spinal Cord Injuries

Primary Outcomes

Description: Treatment Satisfaction Questionnaire

Measure: Treatment Satisfaction

Time: 6 weeks

Secondary Outcomes

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Ability to Participate in Social Roles and Activities

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Fatigue

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Satisfaction with Social Roles and Activities

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Positive Affect and Well-Being

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Pain Interference

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Resilience

Time: Baseline, 6 weeks, and at 3 month follow-up

Description: Spinal Cord Injury - Quality of Life Short Form

Measure: Self-Esteem

Time: Baseline, 6 weeks, and at 3 month follow-up

Other Outcomes

Description: Fear of COVID-19 Scale

Measure: Fear of COVID-19 Scale

Time: Baseline, 6 weeks, and at 3 month follow-up
5 Tracking Needs of Persons With a Spinal Cord Injury (SCI) During the COVID-19 Pandemic

Persons with spinal cord injury (PwSCI) are at a greater risk for major health conditions and poorer health outcomes than persons without spinal cord injury (SCI). They often experience a great deal of health needs both on a physiological level as well as a psychosocial level. PwSCI frequently require supports and services to be able to live independently within the community. These services and supports are sometimes difficult to access within the community when the country is operating under regular capacity, in current times with the global COVID-19 pandemic, the challenges for obtaining and accessing supports and services will become much greater. The proposed project aims to identify the specific needs during this time of crisis and to provide referrals and resources to ameliorate those needs by surveying PwSCI in the St. Louis region. The project also hopes to determine if these persons experience isolation during shelter at home orders. PwSCI, who the investigators serve or have served in the past, will be contacted via phone or e-mail once a month for six months and asked to complete a questionnaire that will allow the investigators to track the participant's needs during the COVID-19 pandemic.

NCT04422769
Conditions
  1. Spinal Cord Injuries
MeSH:Spinal Cord Injuries Wounds and Injuries

Primary Outcomes

Description: Instrumental Support refers to the perception that people in one's social network are available to provide material or functional aid in completing daily tasks (such as making meals or providing transportation) if needed. This self-report measure for adults (ages 18 and above) is an 8-item calibrated scale.This study will use the measure to determine if people's instrumental support changes during a pandemic.

Measure: NIH Toolbox Instrumental Support Survey - change in instrumental support

Time: Baseline, 3 month and 6 month

Secondary Outcomes

Description: A scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation. Participants rate each of the 3 items as hardly ever (score of "1"), some of the time (score of "2"), or often (score of "3"). The scores for each individual question can be added together to give you a possible range of scores from 3 to 9. The higher the score the more lonely the person will be. This study will use the measure to determine if people feel socially isolated during a pandemic.

Measure: UCLA (University of California - Los Angeles) 3-item Loneliness Scale - change in social isolation

Time: Baseline, 3 month and 6 month
6 COVID-19 and Disability: The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries

Document and evaluate the impact of societal restrictions due to the pandemic on SCI- and ABI-related disability and functional impairments, and the resultant effects on psychological wellbeing, physical wellbeing and quality of life for those with SCI/ABI.

NCT04426071
Conditions
  1. Brain Injuries
  2. Stroke
  3. Spinal Cord Injuries
MeSH:Brain Injuries Spinal Cord Injuries Wounds and Injuries

Primary Outcomes

Description: Fear of COVID-19 Questionnaire

Measure: Change in Fear of COVID-19

Time: baseline, 3 months, 6 months

Secondary Outcomes

Description: NeuroQol SF v1.0 - Ability to Part. in SRA

Measure: Change in ability to participate in social roles and activities

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Depression

Measure: Change in depressive symptoms

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Pos. Affect & Well-Being

Measure: Change in positive affect and well-being

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Anxiety

Measure: Change in anxiety

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Fatigue

Measure: Change in fatigue

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Emotional & Beh. Dyscontrol

Measure: Change in emotional and behavioural dyscontrol

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Satisfaction w SRA

Measure: Change in satisfaction with social roles and activities

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Sleep Disturbance

Measure: Change in sleep disturbance

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Stigma

Measure: Change in stigma

Time: baseline, 3 months, 6 months

Description: NeuroQol SF v1.0 - Cognitive Function

Measure: Change in cognitive function

Time: baseline, 3 months, 6 months

Description: 23 questions about strategies to social distance

Measure: Change in social distancing strategies used

Time: baseline, 3 months, 6 months

Description: 22 questions about social distancing

Measure: Change in thoughts and feelings about social distancing

Time: baseline, 3 months, 6 months
7 An Integrated Self-Management Service Delivery Model for Persons With SCI Across the Care Continuum

Persons with spinal cord injury (SCI) face many challenges as they transition from inpatient care to outpatients and on into the community. With shorter lengths of stay and barriers to coordinating care between SCI specialists and community service providers, the development of self-management skills are an integral part in the effective community reintegration, proper healthcare utilization, management of secondary complications as well as independence and community participation. Based on the best available behaviour change theory, this initiative utilizes an online e-health Platform as a key component of a novel care service delivery model to enhance the development of effective self-management skills. This Platform will be provided to participants receiving care in the inpatient or outpatient programs at Parkwood Institute with the potential to continue its use in the community. Participants will complete surveys prior to, during and following use of the e-health solution. These will assess feasibility, usability, usage analytics and several patient-reported outcomes including self-management-related outcomes, healthcare utilization and prevalence of secondary complications. This platform is especially relevant to our current state of dealing with COVID-19 and the challenges it presents for clinicians and their patients in that it will provide an online solution during a time of physical isolation as well as providing access to tools and resources as people transition back to their home communities following specialized rehabilitation services.

NCT04540679
Conditions
  1. Spinal Cord Injuries
Interventions
  1. Other: VIP4SCI
MeSH:Spinal Cord Injuries

Primary Outcomes

Description: Feasibility will be assessed across 4 subdomains (a) acceptance, b) demand, c) practicality, and d) limited efficacy) by the average scores from a set of 5 point likert-style questions relating to each sub-domain as part of a customized feasibility survey based on the Bowen et al feasibility framework (Am J Prev Med. 2009 May; 36(5): 452-457). The overall feasibility will be represented by the average score across all of the sub-domains.

Measure: Feasibility of the use of the platform across 4 sub-domains including a) acceptance, b) demand, c) practicality, and d) limited efficacy

Time: 6 weeks after admission/enrollment (inpatient/outpatient platform access groups), discharge (or 6 weeks after admission if outpatient), and 6 weeks after being provided access to the platform (if Standard Care group)

Secondary Outcomes

Description: This will be assessed using 4 questions from the Social Roles & Activities - Ability to Participate Short Form 10a which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Social Roles & Activities - Ability to Participate

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using 1 question from the Independence Short Form 8a which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Independence

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using 3 questions from the Pressure Ulcers Form 12a which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Pressure Ulcer

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using 3 questions from the Pain Interference Form 10a which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Pain Interference

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using 1 question from the Pain Behaviour Form which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Pain Behaviour

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using 3 questions from the Resilience Short Form 8a which is a subscale in the SCI Quality of Life (SCI-QOL) 1.0 Measurement Tool (Tulsky et al., J Spinal Cord Med. May, 2015; 38(3): 257-269). This is a patient-reported outcome measure involving 5-point, likert-based questions.

Measure: Resilience

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using the Secondary Conditions Scale which involves 4-point, likert-based questions to indicate the degree to which a specific condition is a "problem" (Kalpakjian et al., J Spinal Cord Med. 2007; 30: 62-70). There are 16 questions, each one addressing a different condition (e.g., bowel dysfunction, bladder dysfunction, diabetes, etc) that are common in persons with spinal cord injury.

Measure: Impact of Secondary Conditions

Time: Longitudinal measure assessed at baseline and then at discharge (or 6 weeks) and then again 6 weeks later for follow-up

Description: This will be assessed using the Mobile Application Rating Scale which is a series of 5-point likert-based questions across 6 sub-domains including (a) engagement, (b) functionality, (c) aesthetics, (d) information quality, (e) subjective quality and (f) perceived impact (Stoyanov et al., JMIR Mhealth Uhealth 2015;3(1):e27).

Measure: Quality of Mobile Application

Time: 6 weeks after admission/enrollment (inpatient/outpatient platform access groups), discharge (or 6 weeks after admission if outpatient), and 6 weeks after being provided access to the platform (if Standard Care group)

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook